Skip to content
DataLookout
Menu

NCT07819695

Safety and Tolerability Evaluation of BP-LT

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Nov 1, 2026 to Nov 3, 2026
    • Site details revised
  2. Notable Primary endpoint(s) modified
    • Study title shortened, about 3 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) per arm, by product causality.
Timeframe: From baseline (Day 0) to Day 7

Arms and interventions

BP-LTExperimental

Received test product containing BP-LT

PlaceboPlacebo comparator

Received placebo product without BP-LT

Dietary supplements: BP-LT, Placebo

Sites

1 site in 1 country

  • The International Centre for Diarrheal Disease Management in Bangladesh (icddr,b)Dhaka, Bangladesh